Development of radiopharmaceuticals for PET renography
Renography is a standard clinical diagnostic test frequently used to evaluate renal function inpatients with suspected renal disorders. It is conducted by dynamic planar imaging using technetium-99mrenal agents. Although renography in the current form provides adequate results for certain clinical applications,the planar imaging used in renography restricts its ability in providing accurate quantitative data anddetailed pathophysiologic information. These drawbacks limit the possible use of renography in the earlydetection and monitoring of many renal diseases. The technical limitations of renography associated with theuse of planar imaging can be eliminated by using positron emission tomography (PET). In this regard, severalpotential PET renal agents were developed, which are all listed in this review article. PET renography couldprovide the potential to diagnose renal diseases early and quickly implement appropriate preventive and/ortreatment strategies to improve patient care and reduce the incidence of kidney failure.
Synopsis: Application of positron emission tomography (PET) for renography would significantly increase its clinical value by providing both accurate quantitative data and higher resolution tomographic images compared to the currently used planar imaging. In this regard, several potential PET renal agents were developed, which are all listed in this review article.
Volume 133, 2021
Continuous Article Publishing mode
Click here for Editorial Note on CAP Mode